Successful intravenous thrombolysis in a patient with antiphospholipid syndrome, acute ischemic stroke and severe thrombocytopenia
| Autor: | Catalina J. Andrade-Vazquez, Carlos R. Camara-Lemarroy, Raul V. Enriquez-Noyola, Adrian Infante-Valenzuela, Fernando Góngora-Rivera, Erick García-Valadez |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment 030204 cardiovascular system & hematology Tissue plasminogen activator 03 medical and health sciences Young Adult 0302 clinical medicine Fibrinolytic Agents Antiphospholipid syndrome medicine Humans Thrombolytic Therapy Young adult Intensive care medicine Acute ischemic stroke Stroke business.industry Brain Hematology General Medicine Thrombolysis medicine.disease Antiphospholipid Syndrome Thrombocytopenia Severe thrombocytopenia Tissue Plasminogen Activator Female business 030217 neurology & neurosurgery Fibrinolytic agent medicine.drug |
| Zdroj: | Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 27(3) |
| ISSN: | 1473-5733 |
| Popis: | Alteplase is the only approved drug for the treatment of acute ischemic stroke, but it is offered to a minority of patients, not only because of the short therapeutic window but also because of the numerous contraindications associated with thrombolysis, such as thrombocytopenia. There is some controversy on the true risk associated with thrombolysis in patients with thrombocytopenia. Here we report the case of a young patient, who developed an in-hospital acute ischemic stroke involving a large territory of the right middle cerebral artery, who was successfully treated with intravenous alteplase, despite having thrombocytopenia and prolonged prothrombin times due to systemic lupus erythematosus and antiphospholipid syndrome. This case exemplifies the need to reassess contraindications for thrombolysis, many based on expert opinion and not clinical evidence, especially in complex clinical situations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|